Industry Sectors: Medical Technologies & Services
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Industry Sectors: Medical Technologies & Services

The six members of the BofA team captained by Michael Jüngling enjoy a sixth straight year in the pole position.

Michael Jüngling & team BofA Merrill Lynch


second team Hans Boström Goldman Sachs


third team Julien Dormois & team Exane BNP Paribas


The six members of the BofA team captained by Michael Jüngling enjoy a sixth straight year in the pole position. With offices in London and New York, the analysts win acclaim for their “continued excellence in covering companies on both sides of the Atlantic,” according to one fund man­ager. As the prospect of health care reform loomed in the U.S., the team steered clients away from companies reliant on insurance reimbursement and toward those that provide products with steady demand.


Winning calls include a March buy on Swiss hearing-­aid manufacturer ­Sonova Holding and a May buy on Zurich-­based dental-­implant maker Nobel Biocare. The stocks had gained 92.7 and 33.5 percent, respectively, by the end of the year. Jüngling, 38, left BofA in November and joined Morgan Stanley last month.


Clients say solo analyst Hans Boström, who claims second-­place honors for a sixth consecutive year, provides a “no-­nonsense, value-­intensive” approach and covers “a staggering range of stocks.” The Goldman Sachs International analyst upgraded Swiss dental-­implant manufacturer Straumann Holding to buy in July, at Sf187.50, as a short-term defensive play against uncertainty over U.S. health care reform.


In November, after the stock had shot up to Sf246.30 — an advance of 31.4 percent that led the sector by 11.2 percentage points — Boström told clients to take profits. He closed the call a bit early, however; the stock had climbed to Sf292.50 by December 31.


Newcomer Julien Dormois leads his Exane BNP Paribas trio to a third-place debut. The analysts issued a valuation-­based buy on U.K.-­based medical equipment maker Smith & Nephew in January 2009, at 469p. The stock shot up 36.4 percent, to 639.50p, through ­December.


To go back to the index page, click on the Best European Analysts of the Year: 2010 All-Europe Research Team.


To read the article, click on: Reversal of Fortunes: The 2010 All-Europe Research Team.


Click here to access the complete rankings of the 2010 All-Europe Research Team.


Related

In changing times, Mislav Matejka and his equity strategy team at J.P. Morgan are big vote-getters on the 2017 All-Europe Research Team.
BTG Pactual lands in second place for a second consecutive year.
Bank of America Merrill Lynch advances to second place; BTG Pactual tumbles to third.
Gift this article